98%
921
2 minutes
20
Background And Purpose: Radiotherapy for localized prostate cancer often targets the entire prostate with a uniform dose despite the presence of high-risk dominant intraprostatic lesions (DILs). This study investigated the feasibility of focal dose-averaged linear energy transfer (LET) boost for prostate carbon-ion radiotherapy to deposit higher LET to DILs while ensuring desired relative biological effectiveness weighted dose coverage to targets and sparing organs at risk (OARs).
Materials And Methods: A retrospective planning study was conducted on 15 localized prostate cancer cases. The DILs were identified on multiparametric MRI and used to define the boost target (PTV). Two treatment plans were designed for each patient: 1) conventional plan optimized by the single-field uniform dose technique, and 2) boost plan optimized by the multifield optimization and LET painting technique, to achieve LET boost within the PTV. Dose and LET metrics of the targets and OARs were compared between the two plans.
Results: Compared to the conventional plans, the boost plans delivered clinically acceptable dose coverage (D and D) to the target (PTV2) within 1% differences while significantly increasing the minimum LET by 16 ∼ 24 keV/μm for the PTV (63.9 ± 2.8 vs. 44.0 ± 1.3 keV/μm, p < 0.001). Furthermore, these improvements were consistent across all cases, irrespective of their anatomical features, including the boost volume's size, location, and shape.
Conclusion: Focal LET boost was a feasible strategy for prostate carbon-ion radiotherapy. This investigation demonstrated its superiority in delivering LET boost without depending on tumor location and volume across different cases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869034 | PMC |
http://dx.doi.org/10.1016/j.phro.2025.100727 | DOI Listing |
Small
September 2025
School of Chemistry and Chemical Engineering, Guangxi Key Laboratory of AI-Driven Zero-Carbon Technologies, Key Laboratory of New Low-carbon Green Chemical Technology Education Department of Guangxi Zhuang Autonomous Region, Guangxi University, Nanning, 530004, China.
Sarcosine (Sar), a critical potential biomarker for prostate cancer (PCa), is primarily detected via enzyme cascade reactions involving sarcosine oxidase (SOx) and peroxidase. Nevertheless, the intermediate product hydrogen peroxide (HO) tends to diffuse to the bulk solution phase without entering subsequent reaction, leading to suboptimal detection sensitivity and compromised analytical performance. To tackle this challenge, a multilayered sandwich nanozyme cascade sensor (designated as Cu-MOF/Rf@BDC) is proposed through a confinement-mediated HO enrichment strategy.
View Article and Find Full Text PDFProstate
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Background: The USPSTF recommendation against PSA screening (RAPS) in 2012 resulted in unfavorable changes in prostate cancer (PCa) outcomes. However, the effect on cancer-specific mortality (CSM) in localized PCa has not been assessed.
Methods: Within the Surveillance, Epidemiology, and End Results database (2004-2021), we identified patients treated with radiotherapy (RT) or radical prostatectomy (RP) for localized PCa.
Prostate
September 2025
Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.
Background: Prostate cancer (PCa) is the only cancer in men to exhibit androgen sensitivity at diagnosis, which has allowed for the development of androgen deprivation therapy (ADT). However, outcomes in high-risk PCa (HRPCa) remain significantly worse than low risk disease and the use of ADT varies among treatment algorithms and medical specialties. In men treated with radiation, testosterone recovery after completing ADT has been associated with oncologic outcomes.
View Article and Find Full Text PDFInt Urol Nephrol
September 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.
View Article and Find Full Text PDFEur Urol Focus
September 2025
Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.
Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).